{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:14:41Z","timestamp":1791897281038,"version":"4.3.4"},"reference-count":10,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ocrelizumab is a humanized monoclonal antibody against the B-lymphocyte antigen CD20 and the only approved treatment option in primary progressive multiple sclerosis. Herpesvirus-related infections like cytomegalovirus (CMV) infections are common in patients receiving ocrelizumab, whereas gastrointestinal side effects with inflammatory bowel disease (IBD) like esophagitis or colitis are very rare. This case report describes the challenging clinical, endoscopic, and histologic features of an ocrelizumab-induced colitis overlapping with CMV infection and their disadvantageous interaction with the underlying multiple sclerosis.<\/jats:p>","DOI":"10.1055\/a-2008-0979","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:01:09Z","timestamp":1675468869000},"page":"1500-1503","source":"Crossref","is-referenced-by-count":3,"title":["Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis"],"prefix":"10.1055","volume":"61","author":[{"given":"Sabine","family":"Lieb","sequence":"additional","affiliation":[{"name":"Dept. of Hepatology, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Heni","sequence":"additional","affiliation":[{"name":"Dept. of Gastroenterology, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rauschenberg","sequence":"additional","affiliation":[{"name":"Dept. of Hepatology, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Lange","sequence":"additional","affiliation":[{"name":"Helios Klinik Leisnig, Leisnig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Feisthammel","sequence":"additional","affiliation":[{"name":"Dept. of Gastroenterology, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Bl\u00e4ker","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Wiegand","sequence":"additional","affiliation":[{"name":"Dept. of Hepatology, University of Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis","volume":"14","author":"JM Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"HS Ng","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1093\/ibd\/izaa057","article-title":"First Case of Refractory Colitis Caused by Ocrelizumab","volume":"26","author":"DB Sunjaya","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8858378","article-title":"Ocrelizumab-Induced Severe Colitis","volume":"2020","author":"HH Lee","year":"2020","journal-title":"Case Reports in Gastrointestinal Medicine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.20524\/aog.2021.0582","article-title":"Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis","volume":"34","author":"A Barnes","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e00742","DOI":"10.14309\/crj.0000000000000742","article-title":"Severe Ocrelizumab-Induced Enterocolitis Treated Successfully With Ustekinumab","volume":"9","author":"J Shah","year":"2022","journal-title":"ACG Case Rep J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/0-387-33778-4_10","article-title":"The B-cell system in inflammatory bowel disease","volume":"579","author":"P Brandtzaeg","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/019262339902700124","article-title":"The Role of IL-10 in Inflammatory Bowel Disease: \u2018Of Mice and Men\u2019","volume":"27","author":"MW Leach","year":"1999","journal-title":"Toxicol Pathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1084\/jem.184.1.241","article-title":"T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice","volume":"184","author":"NJ Davidson","year":"1996","journal-title":"Journal of Experimental Medicine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cgh.2019.03.027","article-title":"De Novo Colitis Associated With Rituximab in 21 Patients at a Tertiary Center","volume":"18","author":"JD Eckmann","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2008-0979.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:25:02Z","timestamp":1699575902000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2008-0979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":10,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,9]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2008-0979","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]}}}